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Background: Although the success rate of elective percutaneous coronary intervention (PCI) in stable patients is high, the procedure is associated 
with elevation of cardiac enzymes, suggestive of of myocardial necrosis in up to 50% of cases. Experimental evidence suggests that secretory 
phospholipase A2 (sPLA2) may play a role and that inhibition of this enzyme may have an ameliorating effect. The central hypothesis of the SPIDER 
study is that sPLA2 inhibition will reduce myocardial injury after elective PCI as measured by post-procedural release of cardiac biomarkers CK-MB 
and troponin I. Changes in sPLA2 activity and hsCRP constituted secondary endpoints.
Methods: Exclusion criteria included a recent acute coronary syndrome, CK-MB or troponin I elevation, recent coronary bypass surgery, Class ≥3 
heart failure, LV ejection fraction <0.30, severe valvular disease, chronic inflammatory disease or corticosteroid use, severe liver disease, recent 
active hepatitis, ALT or AST >3 × upper limit of normal (ULN), biliary obstruction with hyperbilirubinemia (total bilirubin >2 × ULN), creatinine >1.5 
× ULN, nephrotic syndrome, known HbA1c >11%, initiation of statin therapy within the preceding 30 days and a history of severe allergy to any 
medication. Patients who agreed to participate were randomized to receive Varespladib 500 mg po bid or placebo from 3-5 days prior to until 5 
days following PCI. Primary endpoint was a composite of troponin I or CK-MB above ULN at 6-8 or 18-24 hours post PCI.
Results: A total of 142 patients were randomized and took study medication. The Varespladib and Placebo groups were similar (age 63±10 vs. 
64±10 years, 19% vs. 15% women; 38% vs 42% diabetic, 29% vs. 28% with prior MI and 71% vs. 75% with Class 2-3 angina. PCI was performed in 
90% and 85% of patients and was successful in 98% in both groups. The composite endpoint occurred in 56.5% and 51.5% in the Varespladib and 
Placebo groups respectively (p=0.55). sPLA2 activity, similar at baseline, was 0.37±0.49 and 3.65±2.75 in subsets of the two groups 5 days post PCI 
(p=0.000002).
Conclusion: By intention-to-treat, inhibition of sPLA2 beginning 3-5 days pre-procedure does not attenuate myocardial necrosis associated with 
elective PCI.
